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Abstract 
 
    Although the cytogenetic status of patients with AML is considered the single most 
important prognostic factor at diagnosis, additional markers are evolving which in 
conjunction with cytogenetics could help better define subsets at high risk for relapse and 
candidates for HSCT in CR1 or subsets of patients who may have a sufficiently favorable 
prognosis as to preclude a major benefit from HSCT in CR1. Between January 2003 and 
December 2009 a total of 192 patients who were diagnosed to have AML who met the 
inclusion criteria were retrospectively and prospectively analysed. Between October 2008 
and December 2009, 41 patients with AML were analysed for the quantitaion of LSCs. 
All 192 patients underwent “3+7” standard induction therapy with Daunorubucin (DNR) 
50mg/m2 on days 1-3 and Cytosine Arabinoside 200mg/m2  on days 1-7. A total of 
117(60.9%) patients achieved complete remission(CR) after induction. There were 47 
(24.5%) induction deaths. 118(61.5%) patients (112 in CR1, and 6 without achieving CR) 
received consolidation therapy. 40(20.8%) patients underwent allo SCT, 25 (13%) auto 
SCT, 39(20.3%)HIDAC, and 14(7.3%) patients received chemotherapy other than 
HIDAC. At a median follow up of two years  the Kaplan- Meier estimate of OS, EFS and  
DFS was 47.30± 4.30%., 37.52± 4.20%  and 54.49±5.38% respectively for the entire 
cohort. The difference in outcomes between the different cytogenetic and molecular 
subgroups well as for the different modalities of consolidation did not show statistical 
significance. The  disease free survival curves for the two subgroups above and below the 
median value (8.12) of  WBC index were significant(p=0.0225). Thus the CD34+ and 
CD34+ CD38- cells in the day 10 to day 14 marrow when quantified and analysed as a 
continuous variable was significant to predict events(p- 0.025 and 0.024 respectively). 
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Introduction 
         Acute myeloid leukemia (AML) is a heterogeneous disorder resulting from 
various genetic and epigenetic alterations that, in turn, lead to abnormal 
differentiation and dysregulated proliferation of hematopoietic progenitors. The 
prevalence of AML is 3.8/100,000 persons under 65 years of age and 18/100,000 
people 65 and older. The paradigm for predicting outcome following induction 
and consolidation therapy depends upon such factors as age, preexisting 
hematologic disorder, history of chemotherapy, white blood cell (WBC) count at 
diagnosis, and cytogenetics. The patient’s cytogenetic profile is uniformly 
recognized today as the most important of these factors; karyotypic evaluation of 
leukemic blasts categorizes AML patients as having favorable, intermediate, or 
unfavorable risk disease. Patients diagnosed with AML at any age who have a 
normal karyotype are categorized as having intermediate-risk disease. However, 
this seemingly homogeneous karyotype conceals a wide variety of different 
molecular abnormalities, many of which confer distinct prognostic significance. 
These include internal tandem duplication (ITD) of the juxtamembrane domain in 
the FMS-like tyrosine kinase-3 gene(FLT3), mutations of the nucleophosmin, 
member 1 gene (NPM1), which results in localization of the gene product to the 
cytoplasm; abnormalities of the gene for CCAAT/enhancer-binding 
protein a (CEBPA), partial tandem duplication (PTD) of the myeloid/lymphoid or 
mixed-lineage leukemia gene (MLL); overexpression of the brain and acute 
leukemia gene (BAALC); and overexpression of the v-ets erythroblastosis virus 
E26 oncogene-like gene (ERG). The evidence for the existence of cancer stem 
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cells (CSCs) was first derived from the study of human AML, largely because of 
the availability of quantitative stem cell assays for the leukemic stem cell (LSC). 
These studies showed that only rare cells within the leukemic clone had the 
capacity to initiate AML growth after transplant into NOD/SCID mice, 
establishing the hierarchial organization of AML. In the present study we have 
tried to analyse the outcome in a young   cohort of patients with AML We tried to 
find out the outcome differences in different cytogenetic and molecular 
subgroups. In a prospective subset of patients we quantified LSCs at diagnosis 
and in post induction marrow to assess its impact in predicting events. 
Review of Literature 
Significant advances have been made in the management of adult acute 
myeloid leukemia (AML) over the past several decades. However, most of these 
advances have been limited to young adults (< 55 years) in whom the average 5-
year disease-free survival (DFS) rate in AML has improved from 11% to 37% 
between 1970 and 20001.Over a similar period in patients who were older than 55 
years at the time of diagnosis, the 5-year DFS for AML has changed marginally 
(6%–12%)1. AML is a heterogeneous disease, thus options of therapy in first 
complete remission (CR1) depends on additional prognostic factors. With current 
induction regimens, 70% to 80% of patients with newly diagnosed AML achieve 
a complete remission; however, this is short-lived without consolidation therapy 
and most, if not all, of these patients will relapse and succumb to their illness2,3. 
Options for post remission induction therapy for AML in CR1 include intensive 
nonmyeloablative consolidative chemotherapy, autologous hematopoietic stem 
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cell transplantation (HSCT), or an allogeneic HSCT. Despite data consistently 
showing a significantly reduced risk of a relapse after an autologous or an 
allogeneic SCT, this has not translated to a significantly better DFS or overall 
survival (OS) because of the counter effect of the treatment-related mortality 
(TRM) associated with these approaches.  
Although the cytogenetic status of patients with AML is considered the 
single most important prognostic factor at diagnosis, additional molecular  
markers like FLT3 and NPM1  are evolving which in conjunction with 
cytogenetics could help better define subsets at high risk for relapse and 
candidates for HSCT in CR14,5 or subsets of patients who may have a sufficiently 
favorable prognosis as to preclude a major benefit from HSCT in CR1. There 
have also been innovations and a steady improvement in the management of 
patients undergoing HSCT that has resulted in lower TRM and improved OS6-10. 
 Since the discovery of LSCs   it has been proved that AML stem cell frequency at 
diagnosis offers a new prognostic factor71 which probably would complement the 
prognostication based on cytogenetics and molecular markers. 
Risk Stratification of Patients with Acute Myeloid Leukemia in 
First Complete Remission:  
Cytogenetics has been the cornerstone of risk stratification in AML4. The 
risk groups based on karyotyping as used by the cooperative groups (Cancer and 
Leukemia Group B, Southwest Oncology Group, and Eastern Cooperative 
Oncology Group) are illustrated in Table 211. The good, intermediate, and 
unfavourable risk groups have 25%, 50%, and greater than 70% probability of 
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relapse and a 4-year probability of survival of greater than 70%, 40% to 50%, and 
less than 20%, respectively12.  This applies to patients < 60 years of age.   
Additional parameters, such as age, white blood cell count at diagnosis, presence 
of certain gene mutations and response to induction chemotherapy can influence 
prognosis, while the type of consolidation therapy could potentially alter the 
predicted outcomes. 
 This risk stratification is particularly useful in making decisions regarding 
the type of consolidation chosen for a patient. In the good-risk group, an 
allogeneic HSCT with a TRM of 15% to 30% will not be the first option when 3 – 
4 cycles of high-dose non-myeloablative consolidation chemotherapy has been 
reported to achieve long-term DFS as high as 70% with a less than 5% TRM. 
However, a more recent analysis involving a larger number of patients than had 
been previously analyzed for this group, suggests that the outcome in the good 
risk group is likely to be lower than that was previously reported, with a ten year 
overall survival of 44% (95% CI 39–50%)13,14. In the unfavorable group, with 
chemotherapy alone, only 10% to 20% of patients are likely to achieve long term 
DFS, thus an allogeneic SCT would be considered acceptable in an effort to 
improve the DFS4. In the intermediate risk group, which constitutes close to 40% 
to 50% of all patients with AML, the options in CR1 are less clearly defined. This 
group is heterogeneous in their response to therapy and most of them have a 
normal karyotype. New markers could help identify subsets at a high risk of 
relapse and candidates for a HSCT. Some such markers, whose role in the 
management of AML is still evolving, are summarized in table 3. Recently it was 
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reported that using a combination of two such gene mutations (NPM1 and FLT3-
ITD), a subset defined as being NPM1+/FLT3-ITD- among patients with a 
normal karyotype had a good prognosis and would probably not benefit from an 
allogenic HSCT in CR115. Although the data on some of these markers are still 
preliminary and remain to be validated in large clinical trials, they illustrate the 
potential of using these markers in risk stratification at diagnosis.  
Induction Therapy 
Modern induction therapy in AML began in the late 1960s, when both cytarabine 
and anthracyclines were shown to have significant activity as single agents. Series 
of classic experiments in the USA by the Cancer and Leukemia Group B 
(CALGB) some 25 years ago established what really became standard of care for 
at least two decades. Data from carefully controlled randomized studies 
established that continuous infusion cytarabine was most effective; 3 + 7 was 
more effective than 2 + 5; daunorubicin (DNR) was less toxic than adriamycin; 
and anythingless than 45 mg/m2 was significantly less effective. Furthermore, 
there was no advantage in giving 200 mg/m2 rather than 100 mg/m2 of cytarabine 
and 6-thioguanine did not improve the overall results of induction. The early 
1990s ushered in a new era, during which newer anthracyclines were 
studied.Based on these studies, standard induction consisted of DNR 45 mg/m2 
intravenously for 3 days and cytarabine 100 mg/m2 by continuous infusion for 7 
days. This has been the standard against which most new regimens have been 
tested. With this regimen 60% to 80% of young adults and 40% to 60% of older 
adults can achieve a complete remission (CR).  
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Post-remission Therapy 
 
           Despite initial high CR rates, the overall survival (OS) of adults with AML 
is unsatisfactory, even in the most favorable cytogenetic groups, such as the core 
binding factor translocations. The need for any post-remission therapy was 
established in the landmark study conducted by the ECOG in 1983 which 
prospectively included an observation arm as part of the post-remission strategy. 
The options for post-remission treatment are broad and the ultimate choice of 
therapy is determined by the prognostic factors at diagnosis and beyond. Clearly, 
patient and physician biases also impact the therapy that is offered. A variety of 
strategies to prevent relapse have been explored. The following is the guideline 
for HLA matched sibling transplant in CR1 based on molecular markers and 
cytogenetics as published in ASH 2009.   
 
Table 1: Guidelines for HLA matched sibling transplant in CR1 – ASH 2009 
 
 
 
 
Autologous Hematopoietic Stem Cell Transplantation (Auto SCT) 
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The early phase II trials of autologous bone marrow transplantation in 
young adults with (< 60 years) with AML in CR1 showed an overall DFS ranging 
from 40% to 60%, relapse rates of 30% to 50%, and a TRM of 5% to 15%. 
Subsequent phase III trials confirmed a reduced relapse risk compared to 
intensive chemotherapy (summarized in Table 4)11,16-18. In two of these trials, this 
reduction translated into an improved DFS; however, there was not a significant 
difference in OS in any of the trials16,21. A recently published meta-analysis 
confirms these observations19. All these reported prospective trials had 
limitations, such as variable numbers of patients who actually received the 
assigned therapy and a high TRM (average of 12%). Most of these trials were 
initiated more than a decade ago and there has been significant interval 
improvement in the management of patients undergoing an autologous HSCT. 
Most large single center data are consistent with our own experience and 
demonstrate no significant difference in TRM compared to high-dose 
consolidation chemotherapy3. This reduction in TRM could potentially translate 
into reduced relapse risk and improved DFS and OS after an autologous SCT. It is 
unlikely that a prospective trial will clarify this in the near future since to show a 
10% difference in survival (P = 0.05, with 90% power), more than 1000 patients 
would need to be enrolled16. From the available data, some generalizations can be 
made. Good-risk group patients would probably not benefit significantly from an 
autologous SCT in CR121.  In the unfavorable group, there are no data to suggest 
a benefit of an autologous SCT over chemotherapy, the outcomes after both these 
options appears dismal4,20. Patients in the intermediate-risk group are candidates 
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for an autologous SCT, especially subsets with a high risk of relapse as defined by 
additional parameters. However, this remains to be validated in large randomized 
clinical trials. 
The conventional conditioning regimen prior to an autologous SCT has 
been a combination of Busulphan and Cyclophosphamide (BuCy)22 or a 
modification of this with reduced dose of cyclophosphamide administered over 
two days (BuCy2)23. The role of Cyclophosphamide (predominantly 
immunosuppressive) in this setting has been questioned and more myeloid 
malignancy specific drugs in the conditioning regimen such as a combination of 
Idarubicin and  Busulphan have been used, the preliminary data with this regimen 
is promising24.         
Role of purging the stem cell product before autologous hematopoietic 
stem cell transplantation: In an effort to reduce relapse, some investigators have 
purged stem cell products before infusion. The agents traditionally used in vitro 
for this purpose include mafosfamide and 4-hydroperoxy-cyclophosphamide (4-
HC). There are retrospective data to suggest that purging is of benefit, whereas, in 
a large prospective trial, purging with 4-HC did not appear to be of significant 
benefit11,25,26. There is insufficient data to strongly recommend purging; however, 
the data is also inadequate to completely exclude a role for purging the stem cell 
product. Other experimental methods of purging the stem cell product including 
exposure to hyperthermia and immunologic purging by positive selection have 
been shown to have potential27,28.    
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Role of consolidation therapy before autologous stem cell 
transplantation: After induction of CR1, additional consolidation chemotherapy 
before an autologous SCT appears to have a significant positive effect by 
reducing the relapse risk and improving the DFS29,30. A recent retrospective 
analysis of the Autologous Blood and Marrow Transplant Registry/International 
Bone Marrow Transplant Registry (ABMTR) database reached a similar 
conclusion40. The optimal consolidation regimen before an autologous SCT 
remains to be defined. Extrapolating from the Cancer and Leukemia Group B 
studies on the optimal consolidation chemotherapy for AML, it would appear that 
high-dose cytosine arabinoside (3 gm/m2 every 12 hours × six doses) 
administered for three or more courses would be ideal2,14. From the published data 
regarding autologous SCT in AML, two or more cycles of high-dose cytosine 
arabinoside-based regimen would appear to be adequate prior to the transplant29 
though the ABMTR data analysis did not show a significant difference when 
either standard dose cytosine arabinoside (<1gm/m2) or high dose cytosine 
arabinoside (1-3gm/m2) was used31. 
Source of stem cells for an autologous stem cell transplantation: Bone 
marrow versus peripheral blood: Retrospective data suggest that the use of 
cytokine-mobilized peripheral blood stem cells (PBSC) for an autologous 
transplant is associated with more rapid engraftment of neutrophils and platelets32. 
However, most studies do not show an improvement in relapse risk, TRM, DFS, 
or OS33.  
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Allogeneic Hematopoietic Stem Cell Transplantation ( Allo SCT) 
             Large prospective trials have consistently shown that an allogeneic SCT 
with standard myeloablative conditioning regimen is the most potent anti-
leukemia treatment for AML in CR1 with a relapse risk of 24% to 36% compared 
to 46% to 61% with autologous SCT or chemotherapy (Table 4)11, 16-18,34. 
However, in none of these trials did this decreased relapse risk translate to a 
significantly improved OS. This was due to high TRM, which ranged from 10% 
to 25%. An allogeneic SCT is not an option to consider for patients in the good 
risk cytogenetic group in CR1 since (i) they have excellent response to therapy 
with high dose chemotherapy and (ii) even if they do relapse after consolidation 
chemotherapy, they still respond well to an allogeneic or autologous SCT in 
CR235,36, . In the intermediate and unfavourable cytogenetic groups, the TRM 
associated with an allogeneic SCT may be acceptable in an effort to improve the 
DFS and OS. In the unfavorable group in CR1, an intergroup study showed a 5-
year survival rate of 44% versus 15% with chemotherapy or an autologous SCT 
(Figure 1), whereas a similar but less dramatic difference was noted in the 
European Organization for Research and Treatment of Cancer/Gruppo Italiano 
Malattie Ematologiche Maligne dell’Adulto AML-10 trial (EORTC/GIMEMA) 
and in the Dutch Belgian Hematolo-Oncology Cooperative Group / Swiss Group 
for Clinical Cancer Research (HOVON-SAKK) study4,37,38. Two other studies 
failed to show an advantage of an allogeneic SCT over chemotherapy or an 
autologous SCT in the unfavorable risk group18,34. In all of the studies, the 
 20
outcome in the unfavorable risk group with chemotherapy alone or with an 
autologous SCT was dismal. Based on the available data, if a donor is available, it 
is reasonable to proceed with an allogeneic-related HLA-identical SCT in CR1 
with unfavourable cytogenetics. In the intermediate-risk group, the data from 
most large prospective clinical trials did not show an improved OS after 
allogeneic SCT in CR1. However, in one study, there was a significant 
improvement in the DFS11,16-18,34. The optimal therapeutic strategy in this group of 
patients in CR1 is still evolving. If a related HLA identical donor is available, 
other parameters could be used to aid in the decision-making process. Some of the 
factors that would favor an allogeneic SCT in CR1 include age of patient (< 40 
years), high white blood cell count at diagnosis (> 30,000–40,000/mm3), 
requirement of more than one cycle of chemotherapy to achieve CR1, and the 
presence of additional molecular markers (Table 3) that predict a high risk of 
relapse39-47. While subsets such as those with NPM1+/FLT3-ITD- would probably 
not benefit from an allogeneic SCT in CR115, as mentioned earlier, the data on 
some of these markers are still preliminary and remain to be validated in large 
clinical trials.   
Role of conditioning regimen on outcome: Two major myeloablative 
conditioning regimens (cyclophosphamide/total body irradiation [TBI] and 
cyclophosphamide/busulfan) have been used and studied in randomized trials. 
There are no strong data to suggest that one regimen is superior to the other, each 
regimen has its merits. In several retrospective studies, the use of a TBI-based 
regimen is associated with lower relapse rates and superior DFS48. In a 
 21
randomized single-center study, the use of fractionated TBI to a dose of 15.75 Gy 
in comparison to 12 Gy was associated with a lower risk of relapse, but it did not 
improve survival because of increased TRM and severe acute GVHD associated 
with the higher dose49. RIC regimens are increasingly being used in allogeneic 
SCT in an effort to decrease regimen-related toxicity and preserve the graft-
versus-leukemia effect. There are limited data on the use of RIC regimens in 
young patients with AML in CR1 and should probably only be considered in the 
setting of a clinical trial. The Medical Research Council AML-15 trial intends to 
allow the possibility of a RIC regimen for patients 35 to 45 years who have a 
matched donor. Even in elderly patients the use of RIC regimens which showed 
promise by reducing the TRM has not translated to improved event free or overall 
survival due to the continued risk of relapse in these patients50.   
Role of consolidation chemotherapy before an allogeneic stem cell 
transplantation: Retrospective analysis of the IBMTR and European Group for 
Blood and Marrow Transplantation (EBMT) data suggest that consolidation 
chemotherapy before an allogeneic SCT does not benefit patients with AML in 
CR151,52. Another retrospective analysis from a single center showed similar 
findings and suggested that multiple chemotherapy courses before an allogeneic 
SCT had a deleterious effect53. 
            Bone marrow versus peripheral blood stem cells: Retrospective analysis 
of the EBMT and IBMTR database showed a benefit for use of PBSC in patients 
with advanced AML, but no benefit was shown in patients with AML in CR1, 
whereas another retrospective study showed a benefit for patients with AML in 
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CR1 who underwent a PBSCT54,55 7. A more recent retrospective analysis of the 
Acute Leukemia Working Party/EBMT registry suggests that there is improved 
outcome with the use of bone marrow versus PBSCT when the dose of bone 
marrow CD34+ cells exceeded 2.7 × 106/Kg56. The only prospective study 
addressing this issue demonstrated earlier engraftment, reduced TRM, and 
improved DFS with PBSCT, but there was no difference in OS57.   
AML in India 
      Treating AML in a developing country like India is a huge challenge. There is 
very limited availability of cytogenetics and molecular markers across the 
country. Moreover, there is very limited data on the treatment outcome   with 
standard chemotherapeutic regimens. Also, there seems to be a higher rate of 
infections including fungal infection and treatment related mortality (TRM) when 
compared to the western data. Presently there are evolving new prognostic 
markers including molecular markers and multiparametric flow cytometry to 
document minimal residual disease. Most of these tests are expensive and are not 
available except in select research institutions. In this context, LSCs are definitely 
a new and exciting area of interest. Quantifying LSCs by a set of 
immunophenotypic markers at diagnosis and during assessment of response to 
therapy should be an inexpensive and easily reproducible test which could predict 
the outcome, resistance to chemotherapy and minimal residual disease. 
Leukemic stem cell 
       The concept that only a subpopulation of rare cancer stem cells (CSCs) is 
responsible for maintenance of the neoplasm emerged nearly 50 years ago; 
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however, conclusive proof for the existence of a CSC was obtained only relatively 
recently. Two unique features characterize adult stem cells: the ability to generate 
new pleuripotent stem cells (to self-renew) and the ability to give rise to 
differentiated progeny that has lost its self-renewal capacity. Leukemia can be 
viewed as a newly formed, abnormal hematopoietic tissue initiated by a few 
leukemic stem cells (LSCs) that undergo an aberrant and poorly regulated process 
of organogenesis analogous to that of normal hematopoietic stem cells. A 
hallmark of all cancers is the capacity for unlimited self-renewal, which is also a 
defining characteristic of normal stem cells. Given this shared attribute, it has 
been proposed that leukemias may be initiated by transforming events that take 
place in hematopoietic stem cells. The cells from the hematopoietic system are 
continually generated from self renewing progenitors in the bone marrow called 
hematopoietic stem cells (HSCs), or blood-forming stem cells, which have been 
isolated in both humans and mice59 60 61 62.The relative quiescence of LSC may be 
a major factor contributing to relapse. Consequently, defining unique properties of 
LSC remains a high priority in order to elucidate the molecular mechanisms 
driving stem cell transformation, and for developing therapeutic strategies that 
specifically target the LSC population63. 
Haematopoietic Stem Cells 
          HSCs can be divided into a long-term subset (LT-HSC), which are capable 
of indefinite self renewal, and a short-term subset (ST-HSC) that self-renew for a 
defined interval only. HSCs give rise to non self-renewing oligolineage 
progenitors, which in turn give rise to progeny that are more restricted in their 
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differentiation potential, and finally to functionally mature cells. Recent studies 
have demonstrated that normal stem cells and cancer cells share the ability to self-
renew and that many pathways classically associated with cancer also regulate 
normal stem cell development. For most cancers, the target cell of the 
transformation events is unknown, but evidence indicates that certain types of 
leukemias arise from mutations that accumulate in HSCs. The first experimental 
evidence to indicate the existence of HSCs was the discovery in 1961 by Till and 
McCulloch 64of a population of clonogenic bone marrow cells capable of 
generating myelo-erythroid colonies in the spleen of lethally irradiated hosts. 
Occasionally these colonies contained clonogenic cells that could be further 
retransplanted into secondary lethally irradiated hosts and reconstitute the 
immune system. These were proposed to be HSCs, i.e., progenitor cells with the 
essential characteristic of self-renewal and differentiation potential for all types of 
blood cells. The development of clonal assays for all major hematopoietic 
lineages together with the availability of multiparameter fluorescence-activated 
cell sorting (FACS) has enabled the prospective purification of HSCs from mice 
and to highly enrich for HSCs from humans according to the cell surface 
expression of specific molecules and their functional read-out in vivo and in vitro 
in stromal long-term colony initiating assays. 
Leukemic Stem Cells in AML 
        Because the clonogenic read-out of the leukemic cells perfectly mirrored the 
difference in clonogenicity among the normal hematopoietic cells, the clonogenic 
leukemic cells were described as LSCs. However, not until 1997, in studies 
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published by Blair and colleagues 65and Bonnet and Dick,66was there a clear 
demonstration that most of the leukemic cells were unable to proliferate 
extensively and only a small, defined subset of cells was consistently clonogenic. 
In these studies, LSCs for human AML were identified prospectively and purified 
as [Thy1-, CD34+, CD38-] cells from various patient samples. Although these 
cells represent a small and variable proportion of the totality of the AML cells 
(0.2–1% depending on the patient), they were the only cells capable of 
transferring AML from human patient to nonobese diabetic severe combined 
immunodeficient (NOD_SCID) mice and were referred as SCID leukemia-
initiating cells or SL-IC.  
        In the studies by Bonnet and Dick using flow cytometry, despite the rarity of 
the CD34+CD38- fraction and the presence of high levels of AML-CFU in the 
CD34+CD38+ fraction, leukemic engraftment could only be initiated from 
CD34+D38- fractions. In keeping with a tradition of naming cells based on 
function, they termed this the SCID leukemia-initiating cell (SL-IC). The 
CD34+CD38- SL-IC generated large numbers of CD34+CD38-cells, AML-CFU, 
and mature blasts. This was proof that the cell population that initiated AML in 
SCID mice was distinct from AML-CFU; a new stem cell was thus identified   in 
AML.67Although some exceptions were reported in subsequent years, a high 
proportion of AML patients show LSC activity in the CD34+CD38- fraction68 69 
70
. Recent studies have suggested that the ability to engraft NOD/SCID mice as 
well as increased frequencies of LSC in AML are prognostic for poor outcomes71. 
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Collectively, these studies provide conclusive evidence for the hierarchy model in 
AML.  
Phenotype of Leukemic Stem Cells 
             Subsequent studies showed that LSCs are also CD34+/HLA-DR-/CD71- 
and fail to express Thy172.73Although this phenotype is quite similar to that of 
normal primitive cells, it was hypothesized that malignant transformation would 
yield changes in LSCs that would allow them to be distinguished from normal 
stem cells. One potential difference between normal and   leukemic cells lies in 
their response to hematopoietic growth factors. Numerous studies have examined 
the cytokine response of primary leukemia cells and demonstrated mitogenic 
activity for IL-3, G-CSF, GM-CSF, SCF, FL, TPO and other factors.74 75 
76Although these studies have focused on bulk populations of leukemia cells, one 
can imagine that differential sensitivity to cytokines may also exist at the level of 
primitive AML cells.  
          Perhaps most central to the criteria by which stem cells are defined is the 
property of self-renewal. As mentioned above, studies by Bonnet and Dick 
demonstrated that human AML stem cells derived from multiple French-
American-British (FAB) subtypes are able to undergo self-renewal77. Expression 
of the three antigens, CD90, CD117, and CD123, differ from normal HSC and 
thereby provide the means to separate normal from AML stem cells. 
          CD 123 is interleukin -3 receptor alpha chain. Total marrow generally has 
about 7% positive cells for CD123, but only about 1% of the population expresses 
the antigen at high levels. The CD34 population of normal marrow also has 
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readily evident CD123 expression, as would be expected for a population known 
to contain hematopoietic progenitors. The labeling profile shown is in good 
agreement with previous studies by Sato et al that have also examined IL-3Rα 
levels on human CD34 cells.78 However, the more primitive CD34+/CD38-
compartment shows no significant expression of CD123 (1%). In contrast, 
primary AML cells displayed high levels of CD123. In both the overall 
CD34+ population, as well as the more primitive CD34+/CD38- 
compartment, greater than 99% of the cells were positive for CD123. CD123 is 
generally expressed at high levels and may be indicative of previously 
uncharacterized aspects of AML biology. Future studies will seek to define the 
biological role of CD123 in human AML and to exploit the presence of this 
antigen as a means to target AML stem cells for destruction.  
         Myeloid leukemias have been extensively characterized with regard to stem 
and progenitor cell involvement. Thus, as a focal point for both scientific and 
therapeutic endeavors, leukemic stem cells (LSC) represent a critical area of 
investigation. LSC appears to retain many characteristics of normal 
Hematopoietic Stem Cells (HSC) as evidenced by a hierarchial developmental 
pattern, a mostly quiescent cell cycle profile, and an immunophenotype very 
similar to HSC. These studies demonstrate that LSC retain key features of normal 
stem cells and are biologically distinct from the bulk of leukemia blast cells that 
do not self-renew. Our understanding of the mechanisms that determine whether, 
where and when a stem cell will self-renew or differentiate is still limited, but 
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recent advances have indicated that the stem cell microenvironment, or niche, 
provides essential cues that direct these cell fate decisions79.  
Stem Cell Niche 
       The existence of a stem cell niche, or physiological microenvironment, 
consisting of specialized cells that directly and indirectly participate in stem cell 
regulation has been verified for mammalian adult stem cells in the intestinal, 
neural, epidermal, and hematopoietic systems. In the light of these findings, it has 
been proposed that a "cancer stem cell niche" also exists and that interactions with 
this tumor niche may specify a self-renewing population of tumor cells.80 The 
stem cell niche is an anatomical unit located in the endosteum within the bone 
marrow cavity that is composed of osteoblasts, osteoclasts and stromal fibroblasts. 
Interactions between stem cells and their surrounding microenvironment, or 
niche, are critical for the establishment and maintenance of stem-cell properties. 
The stem-cell niche has been studied in detail in the adult Drosophila testis. It has 
been shown that integrin-mediated adhesion is important for maintaining the 
correct position of embryonic hub cells during gonad morphogenesis. On the basis 
of these data, it has been proposed that integrins are required for the attachment of 
the hub cells to the ECM, which is essential for maintaining the stem-cell niche.81 
Haematopoietic Microenvironment 
        The Haematopoietic Microenviornment (HM) in the bone marrow consists of 
a heterogeneous population of hematopoietic and non hematopoietic stromal cells, 
their extracellular biosynthetic products, and hematopoietic cytokines82. The 
mesenchymal stromal cells maintain bone remodeling and control the 
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differentiation of hemopoietic cells during the life span83. These cells include 
myofibroblasts, other fibroblastoid cells, endothelial cells, osteogenic 
precursors,adipocytes, and macrophages. These cells produce a complex array of 
extracellular matrix (ECM) molecules consisting of proteoglycans and their 
constituent sulfated glycosaminoglycans, chondroitin, heparan, and dermatan 
species as well as hyaluronic acid.(Table:5 ) In addition, they make a variety of 
interstitial and basal lamina collagens. Stromal cells also synthesize other matrix 
molecules,such as fibronectin, thrombospondin, hemonectin, sialoadhesin, 
laminin, and the tenascin glycoproteins 84 85 
Interaction of Adhesion Molecules on Hematopoietic Precursors and Marrow 
Stroma 
        Hematopoietic progenitors express cell adhesion molecules (CAMs) that can 
be classified into six structurally distinct superfamilies: integrins; selectins; 
sialomucins,including CD34; immunoglobulins; CD44 cell surface proteoglycans; 
and cadherins.86 
Integrins 
          Integrins are a family of glycoproteins consisting of non covalently linked 
heterodimers.87 Integrins are expressed on many cells of the hematopoietic system 
and their functional importance has become apparent in recent years.88 89 90The 
beta 1 common chain (CD29) combines with different alpha chains to form a 
variety of VLA (very late activation antigen) molecules that mediate the adhesion 
of hematopoietic cells to ECM components and ligands on stromal and 
endothelial cells. Very late activation antigen (VLA) or beta 1 integrins are 
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primarily receptors for ECM proteins, with VLAs 1,2,3, and 6 being receptors for 
laminin; VLAs 1,2, and 3 for collagen; and VLAs 3, 4, and 5 for fibronectin.91 92 
93
 
94
 VL A-4 also binds the cellular receptor vascular cell adhesion molecule- 1 
(VCAM- l), which is present on BM stroma95 96. The α4β1 integrin Very Late 
activation Antigen-4 (VLA-4) is an α4 (CD49d)/β1 (CD29) heterodimer. It plays 
a key role in the adhesion of both hematopoietic progenitor cells and leukemic 
blast cells to bone marrow stromal cells which express the vascular cell adhesion 
molecule-1 (VCAM-1) or produce fibronectin. VLA-4 is widely distributed on 
hematopoietic cells, including thymocytes, peripheral blood lymphocytes, 
monocytes, activated T cells, T and B lymphoblastoid cell lines, and myeloid cell 
lines. However, VLA-4 is only weakly expressed on most adherent cell lines 
tested.97CD34 (+) cells express the integrin receptor VLA-4 (β4α1) (CD49d), 
whose ligand is VCAM-1 (vascular adhesion molecule-1) on marrow stromal 
cells and fibronectin in the ECM. VCAM-1 is variably expressed on marrow 
stromal and endothelial cells and can be upregulated by several cytokines, 
including interleukin-1 (IL-1). Because VLA-4 and its ligands are widely 
distributed, specificity is most likely conferred by the coexpression of other 
adhesion molecules and can be modulated by hematopoietic cytokines. The VLA-
4/VCAM-1 interaction is a critical component of the complex process of stem cell 
homing.98 The chemokine and chemoattractant stromal-derived factor 1 (SDF-1), 
another important element in the homing of hematopoietic stem cells to the bone 
marrow, is secreted by stromal cells and strongly upregulates the VLA-4-
mediated adhesion of CD34(+) cells to stroma and ECM fibronectin.99 Early 
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precursors also express VLA-5 (β5α1)(CD49e), which can bind to ECM 
fibronectin. Table 6 illustrates the various adhesion molecule interactions. 
Haematopoietic Microenviornment, Tumor Cells and Drug Resistance 
         In AML, adhesion to stroma is mediated by the combined action of β1 
(principally VLA-4) and β 2 integrins100. This rich environment serves as a safe 
haven for normal and malignant hematopoietic cells. This protection allows tumor 
cells to survive the insult of chemotherapy, leading to minimal residual disease, 
and thereby increases the probability for the development of acquired drug 
resistance.. These complex interactions between leukemic blasts, cellular and 
matrix components of stroma, and cytotoxic lymphocytes, play a critical role in 
determining the fate of small numbers of leukemic cells surviving after cytotoxic 
chemotherapy. 
Adhesion Molecule Expression on Leukemic Cells 
        AML blasts express many of the adhesion molecules identified on normal 
hematopoietic precursors. Studies by the Westmead group in Sydney confirm that 
adhesion of AML blasts, at least in part, is mediated by the interaction of VLA-5 
with ECM fibronectin as well as via both β1 (VLA-4) and β2 (LFA-1) integrin 
interactions with stromal cells101 102 103.  
AML cells adhesion to ECM  
        The adhesion of AML cells to ECM elements may explain the tenacity with 
which residual leukemic blasts may persist in the marrow. As discussed above, 
AML blasts adhere to ECM fibronectin and laminin through the β1 (VLA-4, 
VLA5, VLA-6) and β2 (LFA-1) integrins found on the leukemic cells. Antibody-
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blocking studies show that this only partially accounts for the adhesion and that 
other mechanisms, including CD44 binding, have been invoked.The following 
figure illustrates the interactions of normal and leukemic progenitors with the 
haematopoietic microenvironment. 
 
Figure 1: Interactions of normal and leukemic progenitors with the 
hematopoietic    microenvironment (HM). 
 
 
VLA 4 
          The structure-function relationship of the human integrin VLA-4 (alpha 4/beta 1; 
CD49d/CD29), has been studied in the human B-cell line Ramos by immunochemical 
and functional analysis104. The data reported indicate that VCAM-1 and integrin VLA-4 
are obligatory adhesion proteins in the heterotypic adherence between human LL cells 
and Mesenchymal Stem Cells (MSC). The constitutive expression of VCAM-1 by MSC 
may be partially responsible for retention of leukemia cells in the bone marrow and 
metastasis of lymphomas to the bone marrow.105 Cellular adhesion assays performed on 
non Hodgkin Lymphoma cell lines in the presence of either neutralizing antibodies to 
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VCAM or the alpha and beta subunit of VLA-4 resulted in inhibition of lymphoma cell 
line adhesion to the bone marrow stromal line106. Both VLA-4 and CXCR-4 have been 
proposed as mechanisms for retention of AML blasts in the marrow. Functional 
inhibition of either of these receptors has been shown to dislodge AML cells and enhance 
chemotherapy-induced apoptosis in vitro and improve eradication of leukemia in vivo.107 
Liesveld et al108 have shown that human AML cells adhere to long-term BM stromal 
cultures.  They showed that the binding of AML blasts to fibronectin is mediated by 
VLAs 4 and 5, with VLA-5 dependent adhesion predominating. 
         In patients with AML, VLA-4 expression has been associated with bone-marrow 
minimal residual disease, which causes relapse after chemotherapy109. Matsunaga  et 
al110found that VLA-4-positive cells acquired resistance to anoikis (loss of anchorage) or 
drug-induced apoptosis through the phosphatidylinositol-3-kinase (PI-3K)/AKT/Bcl-2 
signaling pathway, which is activated by the interaction of VLA-4 and fibronectin110. 
This resistance was negated by VLA-4-specific antibodies. In a mouse model of MRD, a 
100% survival rate was achieved by combining VLA-4-specific antibodies and Cytosine 
Arabinoside (AraC), whereas AraC alone prolonged survival only slightly. In addition, 
overall survival at 5 years was 100% for 10 VLA-4 negative patients and 44.4% for 15 
VLA-4 positive patients. Thus, the interaction between VLA-4 on leukemic cells and 
fibronectin on stromal cells may be crucial in bone marrow MRD and AML prognosis. 
       Matsunaga et al reported no deaths in 10 patients they classified as negative for  
VLA 4 expression (18.6%), who had median follow-up more than 3 years, whereas in a 
recently published  study 13 of 23 patients with VLA 4 expression less than or equal to 
18.6% died within 12 months. Potential differences between this study and the previously 
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reported study include heterogeneity of patient inclusion criteria, choice of chemotherapy 
regimens, and duration of treatment. In addition, the activation state of VLA 4 integrin, 
which could have influenced the outcome in a small group of patients, was not assessed 
in the previous study. 
VLA-5 
       It has been demonstrated by van der Loo et al that VLA-5 is expressed on primitive 
mouse and human hematopoietic cells and they suggested that there may be significant 
cooperation between integrin receptors and proteoglycan molecules in the engraftment of 
bone marrow cells and hematopoietic cell adhesion in vivo111. Messinger et al. suggested 
that the expression of VLA-4 and VLA-5 on t(1;19) or t(4;11) leukemia cells likely 
determines their binding capacity to bone marrow stroma112. However there has been no 
reported literature on the adverse impact of expression of VLA-5 in blasts/leukemic stem 
cells on the outcome in AML.  
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Table 2: Risk group stratification based on cytogenetics at diagnosis 
Good risk:  t(15;17) 
(10-15%)  t(8;21) 
   inv16, t(16;16) 
 
Standard risk:  Normal karyotype 
 (65-75%)  del (9q) 
             -y 
   del 12 p 
   Trisomy 8 
   t(9;11) 
    
    
Poor risk:  Abnormal 5 or 7 
(15-20%)  inv3q 
   del 20q 
   del 21q 
   t (9;22) 
            t (6;9) 
            non-t (9;11)  11q23 abnormalities with MLL rearrangements  
   complex cytogenetics (3 or more clonal abnormalities)  
 
Modified from Cassileth et al11 
 
 
 
Table 3: Newly identified prognostic markers used in the management of 
AML. 
 
Marker Summary 
FLT3-ITD39,40 Reported in 15 – 35% of cases with AML. Presence associated 
with an adverse outcome 
BAALC gene over 
expression41 
Brain and acute leukemia cytoplasmic (BAALC) gene over 
expression has been shown to predict poor survival in patients 
with AML and normal cytogenetics 
bcl-2 and WT142 Coexpression of apoptosis-related genes bcl-2 and WT1 has 
been associated with significantly inferior DFS and OS 
Evi-1 mRNA43 Over expression of Evi-1 mRNA in patients with intermediate 
risk (by conventional cytogenetics), even in the absence of 
cytogenetic 3q26 abnormalities, identifies a subset with a worse 
prognosis 
Partial tandem 
duplication of the 
Partial tandem duplication of the MLL gene in one study was 
seen in 7.7% of patients with a normal karyotype and associated 
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MLL gene44 with a significantly shorter remission duration 
FADD protein 
expression45 
Absence of Fas-associated death domain (FADD) protein 
expression in AML has been associated with a worse outcome. 
Mutations in 
CCAAT/enhancer-
binding protein−α46 
Several studies, most recently by Frohling et al58, have 
demonstrated that mutations in the transcription factor 
CCAAT/enhancer-binding protein−α are associated with a good 
prognosis. 
VEGFR-1 levels47 Plasma soluble vascular endothelial growth factor receptor-1 
levels have been shown to have an inverse correlation with the 
attainment of CR after induction chemotherapy in AML. 
NPM1 mutations58 The nucleophosmin (NPM1) gene mutations occur in 50% to 
60% of adult AML with normal karyotype (AML-NK). NPM1 
mutations in absence of FLT3-ITD identify a prognostically 
favorable subgroup in the heterogeneous AML-NK category. 
 
Table 4: Relapse risk in phase III trials comparing nonmyeloablative chemotherapy, 
autologous SCT and allogeneic SCTs: 
 
 
Study Allogeneic (%) Autologous (%) Chemotherapy (%) 
GIMMEMA17 24 40 57 
GOELAM18 28 45 55 
MRC16 19 35 53 
ECOG/SWOG11 29 48 61 
 
 
 
 
 
Table 5: Extracellular matrix constituents 
 
 
Proteoglycans and constituent glycosaminoglycans 
         Heparan sulphate 
         Chondroitin sulfate 
         Dermatan sulfate 
         Hyaluronic acid 
 
Collagen types I,III,IV,V,VI 
Fibronectin 
Thrombospondin  
Sialoadhesin 
Laminin 
Tenascin 
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Table 6: Adhesion Molecule Interactions 
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OBJECTIVES AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 39
 
Objectives and aims of study  
1. To study the clinical profile of newly diagnosed patients with AML undergoing 
standard induction and post remission therapies. 
2. To study the incidence , impact  and the clinical outcome of  the molecular markers 
FLT3 ITD, FLT3 TKD and NPM1 mutations  in the above cohort of patients. 
3. To quantify the proportion of leukemic stem cells (LSC) by a set of immuno-
phenotypic markers among the blast population in cases of AML at diagnosis and in a 
post induction bone marrow sample. 
4. To identify and quantitate the expression of adhesion molecules VLA-4 andVLA-5 in 
this LSC population at the same time points.  
5. To correlate the above parameters with the clinical outcomes such as achievement of 
 complete remission (CR), induction death, relapse, event free survival, overall 
 survival and disease free survival. 
Hypotheses 
1. The leukemia characteristics and the treatment outcome in Indian patients might be 
different   from   the data from the west. 
2. Autologous SCT will be superior to high dose consolidation chemotherapy alone in the 
intermediate risk group without a donor in view of the markedly reduced transplant 
related mortality and allogenic SCT will be superior to the other two modalities of 
consolidation.  
3. The prognostic value of the molecular markers FLT3 and NPM1 mutations in 
determining the treatment outcome in Indian population could be different from the 
Caucasian data. 
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4. The number of LSC in the blast population impacts the response to therapy and risk of 
relapse and the residual number of LSC at the end of induction chemotherapy will predict 
relapse. 
5. The expression of adhesion molecules (VLA-4 and VLA-5) on the LSC aids in binding 
these cells to the bone marrow stroma which in turn protects it from the apoptotic action 
of chemotherapeutic agents and high levels expression of these adhesion molecules on 
LSC will predict response to therapy.  
Inclusion Criteria (All) 
1 .Patients with newly diagnosed non M3 AML >=15 years   and <=60 years of age. 
2. Those who have received   standard “3+7 “(Daunorubicin and Cytosine Arabinoside ) 
or equivalent induction therapy during the  study period. 
Exclusion Criteria (Any) 
1.  Patients outside the range of the age group mentioned above. 
2. Those who have been treated with truncated “3+7” or other types of induction 
therapies 
3. Patients previously treated in outside centres. 
4. Patients with AML who presented to our centre at relapse or who were referred only 
for stem cell transplantation. 
Study design 
         This was a descriptive study design. All newly  diagnosed cases of Acute Myeloid 
Leukemia excluding APML in the age group 15-60 years in the hospital between January 
2003 to December 2009 and who have been treated with standard  induction therapy were 
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included. This included a retrospective analysis from January 2003 to December 2008 
and a prospective cohort from January 2009 to December 2009. 
Patients 
       For the retrospective analysis patient records in the Haematology department 
database   were searched and the data sheet of   all patients  who were admitted  during 
the time period were collected. (n= 419 see the flow chart 1). Those patients who were 
discharged without induction chemotherapy were not included. Of  those  patients who 
underwent induction chemotherapy, those < 15 years, >60 years, upfront relapsed cases, 
those who had taken induction treatment from outside centres and those who  received 
truncated  induction therapy were excluded  from the final analysis. Patients who were 
prospectively inducted also met the inclusion criteria. The patients had a complete blood 
count, liver and renal function tests, LDH, bone marrow aspirate, biopsy 
,immunophenotyping and cytogenetics done at diagnosis.         
Bone Marrow Aspirate  
       Bone marrow was aspirated and core biopsy taken at diagnosis.  The bone marrow 
aspirate smears from patients with AML were stained with May Grunwald Geimsa , 
sudan black B , periodic acid schiff , chloroacetate esterase and  alpha naphthyl acetyl 
esterase. The bone marrow blast percentage was quantified and a white blood cell index 
was calculated∗. The Auer rods were documented if present. FAB classification was used 
to subtype. 
                                                 
∗
 Ste´phanie Nguyen et al . Awhite blood cell index as the main prognostic factor in 
t(8;21) acute myeloidleukemia (AML): a survey of 161 cases from the French AML 
Intergroup. Blood.  2002; 99:(10) 3517-3523. 
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                              Flow chart(1) depicting the patient selection. 
.  
 
 
 
Total cases from 1985-2008 
(631) 
Total cases from 2003-2008 
(419) 
Treated 
(249) 
Not treated 
(170) 
Less than 15 years 
(29) 
More than 60 years 
(10) 
Other than “3+7” treatment and relapsed  
cases  
(47) 
163 underwent standard “3+7” induction 
(from 2003-2008) 
29 patients from the LSCcohort(2009) were 
analysed with the 163 above(163+29=192). 
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Immunophenotyping 
           The bone marrow samples were also tested for immunophenotyping on a 4 colour 
FACS Calibur flow cytometer using mouse anti human monoclonal antibodies  in the 
acute leukemia panel as described in the figure below. The fluorochrome  isotypes used 
were IgG1 conjugated FITC, APC PE and PE-Cy5.We followed the EGIL scoring system 
in case of ambiguity in lineage.  The percentage expression of the antigens in the gated 
population was quantified.  The protocol we followed is briefly described below. 
Protocol for sample preparation by Lyse-Wash Method for Immunophenotyping of 
hematolymphoid neoplasms (bone marrow and peripheral blood samples) using CD45 
as a gating strategy 
        Heparin anticoagulated   500ul bone marrow apirate sample was mixed with   3ml of 
RBC-lysis solution (NH4Cl based) and mixed thoroughly. The sample was then 
centrifuged   at 800g for 3 minutes and supernatant was discarded One  ml of phosphate 
buffered saline (PBS) buffer  was added so as to make total volume of 2 ml and gently 
vortexed the pellet so as to break it. Then it was centrifuged at   800g for 3min. PBS   was 
added so as to make 2 ml, pellet was broken and centrifuged once again, and final volume 
was adjusted so as to attain a cell count between 500,000-1,000,000 /mm3. An 
appropriate quantity of antibody from the cocktail mix (determined by antibody titration) 
was added to the cell suspension for the corresponding tube. Sample was incubated in 
dark for 20 minutes. Two ml of PBS   was added   and then washed and centrifuged at 
800g for 3 min. PBS was added to make final volume of 200ul.The following table 
illustrates how the panel was designed. 
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                       Table 7:Design of the tubes for flow cytometry 
 
 
 
Cytogenetics 
Culture  set up for bone marrow samples 
      Bone marrow aspirate samples were received in vacutainers with heparin as the 
anticoagulant. WBC diluting fluid was added and the cell count was taken in Neubauer 
chamber. Then appropriate volume   of the sample was added   to the RPMI culture 
medium. For one bone marrow sample two   RPMI media were used. For one 5ml 100 
microlitre of Colcimed was added and overnight incubation done. In the other   5 ml 250 
microlitre of Colcimed was added and incubated for 30 minutes.  
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Harvest 
      This was done at 17-23 hours after culture setup. After adding Colcimed   the sample 
is incubated, fixative was added and then centrifuged at 1000 rpm for 10 minutes. The 
supernatant was discarded and the pellet was resuspended in fixative. 
Slide making 
       Glass slides were soaked in methanol in koplin jar. They were then wiped dry, 
dipped again in methanol and then swirled in milli Qwater. Cell suspension was then 
dropped on to the slide. Slides were then dried and examined under phase contrast 
microscope.  
 Banding 
        The slides were dipped in warmed trypsin solution. Then they were washed in ice 
cold water and stained with Leishman stain. Stain is blotted and examined under 
microscope. The metaphases (at least 20) were captured and analysed. 
Molecular Markers 
Screening for FLT3-ITD and NPM1 mutations  
         Mutation screening in these two genes were done using Multiplex-PCR followed by 
Gene Scanning. DNA was extracted from cytogenetic cell pellet. Cells (1 x106) were 
fixed in methonal-acetic acid(3:1), 70% ethanol,or 95% ethanol to a 1.5ml 
microcentrifuge tube and centrifuged at 13,000 for 2 mins to pellet cells. After removing 
the supernatant, 300ul cell lysis solution was added to the cell pellet and mixed. To this 
2ul of Puregene Proteinase K (cat.no.158918)  was added  and the sample was incubated 
overnight .Then 100ul of Protein precipitation solution was added  and  centrifuged for 3-
5 min at 13,000 rpm. The protein pellet was precipitated and if protein pellet was not 
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tight, the sample was incubated on ice for 5 mins and repeat centrifugation done. To the 
supernatant 300ul isoproponal was added and centrifuged for 1 min at 13,000-16,000g. 
The supernatant was then discarded and the DNA pellet was washed with 300microlitre 
of 70% alcohol. The sample was then centrifuged for 1 min at 13,000-16,000g.The 
supernatant was discarded and the pellet was air dried. 50ul of 1xTE buffer was added   
to dissolve the DNA.  The sample was incubated   at 370 C overnight.
         Mutiplex-PCR amplification of genomic DNA using primers to exon 14 & exon 
15 of FLT3 yielded a 330 bp from the wild type alleles and primers to exon 12 of 
NPM1 yielded a 169bp from the wild type alleles. HBG gene 469bp served as the 
internal control. FLT3/ITD mutation produced larger peaks with a range from 349 to 
409, 21 to 81bp larger than the wild type, while NPM1 mutation produced   a single 
peak at 171bp, 4bp larger than the wild type. HBG   showed 469bp  peak. 
Treatment 
Induction 
      All patients underwent standard “3+ 7” induction chemotherapy with Daunorubicin  
50 mg/m2 on days  1-3 and Cytosine Arabinoside 200 mg/m2 as a continuous infusion on 
days 1- 7 .All patients were started on amphotericin prophylaxis 0.5 mg/kg /day on 
alternate days  at the start of the chemotherapy and the dose increased  to  1mg/kg/day at 
the onset of febrile neutropenia. This is based on the high incidence of fungal infections 
in our population. Early response assessment marrow was done between days 10-14, and  
if the same showed >20% blasts  with cellularity>20%, a reinduction was considered. 
Persistence of disease documented by bone marrow after second course of induction was 
defined as primary refractory disease. Therapy of such patients was individualised. G 
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CSF was administered after early response assessment at the discretion of treating 
physician. 
Consolidation 
         High dose cytosine arabinoside(HIDAC), autologous stem  cell transplant (auto 
SCT) and  allogentic stem cell transplant (allo SCT) were the principal options 
considered for patients in good general condition, without  co morbidities  and financial 
restrains. Patients with good risk cytogenetics who achieved CR were offered three doses 
of HIDAC. Patients with   intermediate and poor risk cytogenetics were offered allo SCT 
if an HLA matched donor was available. For those with intermediate risk cytogenetics 
without a donor auto SCT was offered. 
High Dose Cytosine Arabinoside (HIDAC) 
        Indications  included 1)good risk AML  and 2)Intermediate risk AML in whom  an  
HLA matched  donor was not available and where it was felt that the general clinical 
condition or co morbid conditions or financial restrains preclude the use of an autologous 
SCT. It consists of high dose cytosine 3gm/m2 q12h on days 1, 3 and 5 and was iniatiated  
one to two weeks after documentation of remission during induction chemotherapy. Each 
dose was diluted in 500ml normal saline and infused over three hours. Cerebellear signs 
were checked for prior to each dose and prednisolone eye drops were started 24 hours 
prior to onset of chemotherapy. 
Intermediate Dose Cytosine Arabinoside 
     This was considered in the following situations- 1) Limited financial resources  
2) Patients with co morbid conditions limiting the intensity of therapy. 
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Autologous Stem Cell Transplant (auto SCT) 
      Indications- Intermediate risk AML in whom an HLA matched donor was not 
available. Patients received 2-3 cycles of HIDAC prior to the mobilization of autologous 
SCT harvest. G CSF mobilized peripheral blood stem cells were harvested between 2-4 
weeks after recovery from last cycle of HIDAC. Conditioning consisted of conventional 
Busulfan and Cyclophosphamide regimen. Minimum target cell dose to proceed with an 
autologous SCT was 2 x 10^8 MNCs/kg. Post autologous GCSF was started on day+7 till 
ANC>1500/mm3 on two successive days. 
Allogenic Stem Cell Transplant (allo SCT) 
     Indication for allogenic SCT included all intermediate and high risk patients with 
AML who had an HLA matched sibling. Conditioning regimens included standard 
myeloablative Busulfan/Cyclophosphamide regimen and reduced intensity conditioning 
(RIC) regimens like Fludarabine Melphalan and FLAG IDA Melphalan. Currently for 
patients scheduled to receive an Allogenic SCT no consolidation is used post induction 
unless there is an anticipated delay in proceeding to transplant. All patients received a 
peripheral blood stem cell transplant. GVHD prophylaxis consisted of conventional 
Cyclosporine/Methotrexate regimen. In the absence of GVHD, Cyclosporine taper was 
initiated from day 60 and stopped by day 100. In the event of GVHD, the taper of 
immunosuppression was individualised. 
LSC study 
        All newly  diagnosed as well as relapsed  cases of AML  in the hospital between 
October 2008 to December 2009  who  consented for the study and who have been 
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treated with standard  induction therapy were included in the study for quantitation of 
LSCs. The study was reviewed and approved by the institution’s research and ethics 
committee (IRB Min No.6661 dated17.09.2008). To be included in the analysis, the 
diagnosis had to be confirmed by bone marrow morphology with cytochemistry or 
immunophenotyping. A written informed consent was obtained from all patients in 
accordance with the Declaration of Helsinki.  All the bone marrow aspirate samples(5 ml 
heparin anticoagulated) from patients with AML were processed for immunophenotyping 
(using antibodies against CD34, CD38 and CD123) to quantify the proportion of 
leukemic stem cells (LSC) among the blast population of newly diagnosed cases of acute 
myeloid leukemia (AML) at diagnosis and in a post induction( day 10-14) bone marrow 
sample. Second, we also identified and quantified the expression of adhesion molecules 
VLA-4 and VLA-5 in this LSC population. An absolute number of cells expressing  these 
markers were quantified by dual platform method.(Bone marrow total nucleated cell 
count  was measured in Sysmex cell counter).The impact on prognosis  was  assessed by 
the correlation with leukemic stem cell and adhesion molecule expression and effect on 
outcome as measured by Overall Survival, Event Free Survival and Disease Free Survival 
. The gating strategy we adopted is described below in figure 2. 
 
        The isotypes and the antibodies directed against specific antigens were run through 
titration experiments to find out the optimum volume. The fluorochrome conjugated 
antibodies were designed in three tubes as described in table 8. CD 44 conjugated with 
FITC did not yield optimum  results with the  titration and hence  the results from the 
tube containing CD 44  was  not  considered for final analysis. PE Mouse Anti-Human 
 50
Gated on CD34+CD38-
LSC (CD34+CD38-CD123+)= 1.43% is 
gated from CD34 VS CD123 scatter plot
Flowcytometry lab,
Department of Haematology,
Christian Medical college.
Cell adhesion molecules/ Integrins such 
as 
•CD44v (H-CAM)
•CD49d (VLA-4)
•CD49e (VLA-5) are further 
quantified  from the corresponding 
scatter plots
Eg VLA-4 expression on LSC.
 
 
Gating Strategy for the LSC study. 
 
LSCs were defined as CD 34+CD38-CD123+ cells. The gating strategy  adopted is 
illustrated here. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Gating strategy for the quantitation of LSCs 
 
CD49dwhich reacts with the integrin alpha 4 chain expressed as a heterodimer with beta 
subunit1 to form VLA 4 and Phycoerythrin conjugated Mouse Anti Human CD49e which 
CD34+CD38-
Flowcytometry lab,
Department of Haematology,
Christian Medical college.Enumeration of Leukemic Stem Cells by flowcytometry  
AML blast population is gated from 
forward scatter versus side scatter plots
CD34+CD38-cells are analyzed from 
secondary scatter plots (CD34 Vs 
CD38). This population is further 
analyzed for CD123 expression
Gated on Blast population
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reacts with the alpha 5 integrin that assoaciated with beta 1 integrin to form VLA5 were 
used to identify adhesion molecules. All the antibodies were bought from BD 
biosciences. The tube design is depicted in the following table. 
 
           Table 8:Design of tubes for flowcytometry for the LSC study 
 
Tube 1(isotype 
controls) 
Tube 2 
 
Tube 3 
 
IgG1 FITC    
3 microlitre 
 CD 34 FITC     
5  microlitre 
CD 34 FITC     
5   microlitre 
 
IgG1PE         
2 microlitre 
 
  CD 49e PE          
5  microlitre 
 
 CD 123 PE           
 5   microlitre 
 
IgG1PE-Cy5 
3microlitre 
 
CD 123 PE-Cy5  
5   microlitre 
CD 49d PE-Cy5  
5   microlitre 
 
IgG1 APC     
2 microlitre 
 
 
  CD 38 APC        
 3   microlitre 
 
 CD 38 APC      
3    microlitre 
 
 
 
DEFINITIONS 
Response criteria in AML 
Complete remission (CR) Bone marrow blasts < 5%; absence of blasts with Auer rods; 
absence of extramedullary disease; absolute neutrophil count > 1.0 x 10^9/L (1000/_L); 
platelet count > 100 x10^9/L (100 000/_L); independence from  red cell transfusion.  
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Induction Mortality:  Death during standard induction treatment for AML. 
Relapse: Bone marrow blasts > 5%; or reappearance of blasts in the blood; or 
development of extramedullary disease 
Event: Death , relapse or persistent disease after two cycles of induction therapy were 
considered as event. 
Outcome measures in AML 
Category Definition 
Overall survival (OS) 
    Defined for all patients. Measured from the date of diagnosis to the date of death from 
any cause; patients not known to have died at last follow-up are censored on the date they 
were last known to be alive. 
Disease free survival (DFS) 
    Defined only for patients achieving CR ; measured from the date of achievement of a 
remission until the date of relapse or death from any cause; patients not known to have 
relapsed or died at last follow-up are censored on the date they were last examined 
Event free survival (EFS) 
    Defined for all patients. Measured from the date of diagnosis to the date of induction 
treatment failure,or relapse from CR  or death from any cause; patients not known to have 
any of these events are censored on the date they were last examined 
Relapse free survival (RFS) 
    Defined for all patients and measured from the date of diagnosis until the date of 
relapse or induction  failure; patients not known to have relapsed are censored on the date 
they were last examined. 
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Statistical analysis 
The chi- square or Fisher exact test was used to compare differences between groups for 
response to therapy. The probability of survival was estimated with the use of the 
product-limit method of Kaplan and Meier for overall survival, event-free survival, 
relapse free survival and disease-free survival and compared by the log-rank test. All 
survival estimates are reported +/- 1 SE. The relationships of clinical features to outcome 
were analyzed by Cox proportional hazard model. All P values were 2-sided, with values 
of .05 or less indicating statistical significance. Statistical analysis was performed using 
SPSS 11.0 software (SPSS,Chicago, IL). 
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RESULTS 
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  Between January 2003 and December 2009 a total of 192 patients who were diagnosed 
to have AML who met the inclusion criteria were retrospectively and prospectively 
analysed. Between October 2008 and December 2009, 41 patients with AML were 
analysed for the quantitation of LSCs. 
Baseline Characteristics (Table 9) 
       Out of the 192 patients,120(62.5%) were males and 72(37.5%) were females .The 
median age was 36 years(range 15-60 years).Among the FAB subtypes, M2 was the most 
common with 95(49.5%) patients, followed by M1 with 39(20.3%) patients. The median 
WBC count at diagnosis was 12.6x109/L (0.4-326x109/l). Median WBC index at 
diagnosis was 8.12(0.10-285). Cytogenetic data was available for 180 patients (93.8%) of 
which 21 (10.9%) were good risk, 121(63%)) were intermediate risk and 38(19.8%) were 
poor risk. Twelve cases had cytogenetic failure.  
    The immunophenotyping data was available for 152 patients, out of which CD13 was 
positive in 115(75.65%) patients, CD33 in 132(86.8%), CD34 was positive in 84(55.3%) 
and HLA DR in 126(82.9%)(figure 3). Bone marrow aspirate of 156(81.3%) patients 
stained positive for Sudan Black B and Auer rods were present in 36(18.8%). 
       Among the cohort of 41 AML patients who were analysed for the quantitaion of 
LSCs 25(61%) were males and 16(29%) were females. The median age was 34 years 
(range 5-59). In addition to the newly diagnosed AMLs 6 cases of relapsed AMLs were 
also included in the analysis.The baseline parameters  of this cohort is summarized in 
table 9.  
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                                      Table 9: Baseline characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 

 blast was defined  as per WHO classification 2008 
∗
 information was available for 184 patients 
 
Variable 
 
 
          Median/n(range) /(%) 
AML  
n = 192 
AML LSC analysis 
n=41 
Age 
<15 years 
15-30 years 
31-40 years 
41-50 years 
51-60 years 
36(15-60) 
0(0) 
66(34.5) 
52(27) 
45(23.4) 
29(15.1) 
34(5-59) 
3(7.3) 
11(26.8) 
13(31.7) 
9(22) 
5(12.2) 
Sex  
Male 
Female 
 
120(62.5) 
72(37.5) 
 
25(61) 
16(39) 
AML FAB 
subtype 
M0 
M1 
M2 
M3 
M4 
M5 
M6 
M7 
Secondary  AML 
Relapse 
 
 
15(7.8) 
39(20.3) 
95(49.5) 
0(0) 
18(9.4) 
12(6.3) 
6(3.1) 
3(1.5) 
4(2.1) 
0 
 
 
0(0) 
12(29.3) 
17(39) 
0(0) 
1(2.4) 
3(7.3) 
0(0) 
2(4.9) 
1(2.4) 
5(14.6) 
Hb in gm/dl 
WBC x 109/l 
Platelet x  109/l  
Peripheral blood 
blast% 
Bone marrow blast 
%    
8.8(3.8-14.0) 
12.6(0.4-326) 
50(2.0-387) 
 
 44.5(0 -98) 
 
70(21-100) ∗ 
 
8.4(4.9-13.7) 
26.4(1.9-152) 
39(5.0-249) 
 
69(1-95) 
 
76(20-100) 
Cytogenetics  
Good 
Intermediate 
Poor 
Not worked/not 
available 
 
21(10.9) 
121(63) 
38(19.8) 
12(6.3) 
 
03(7.3) 
31(75.6) 
07(17.1) 
0 (0) 
LDH 766(113-15220) 1173(290-8374) 
LFT  
Normal 
abnormal 
 
176(91.7) 
16(8.3) 
 
35(85.4) 
06(14.6) 
Creatinine 0.9(0.5-2.3) 0.9(0.4-1.9) 
WBC  index 8.12(0.1-285) 17.33(0.8-91.53) 
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Median values        62.5               73.3               38.9               74.6 
 
 
 
 
            
                        Figure 3: Immunophenotypic characteristics of patients. n=152. 
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Treatment related variables 
Induction (Table 10) 
        All 192 patients underwent “3+7” standard induction therapy with Daunorubucin 
(DNR) 50mg/m2 on days 1-3 and Cytosine Arabinoside 200mg/m2  on days 1-7. Bone 
marrow aspirate and biopsy to assess aplasia done between day 10-14 showed residual 
disease in 33(17.2%) patients. Bone marrow assessment was not done in 10(5.2%) 
patients who died before day 10. A total of 117(60.9%) patients achieved complete 
remission (CR) after induction with “3+7” chemotherapy. There were 47 (24.5%) 
induction deaths. Out of the remaining (n=28), 19(10.4%) underwent second induction. 
Out of these, 12 achieved complete remission. The choice of chemotherapy for the 
second induction varied based on the discretion of the treating physician and included a 
repeat “3+7” chemotherapy, HIDAC, FLAG IDA or “3+3” chemotherapy with Idarubicin 
and high dose Cytosine. In one patient Gemtuzumab Ozagamicin was used as single 
agent for second induction. Thus the overall CR after induction therapy was 
129(67.15%).The causes of induction deaths is enumerated in Table 12.  Invasive fungal 
infection was documented in 33/47(70.2%) induction deaths. There were documented 
bacterial infection in 18(9.4%) out of which 14(7.3%) had gram negative and 4(2.1%) 
had gram positive infection. Invasive fungal infection was documented in 
85(44.3%).According to the International Consensus criteria 81(42.2%) were classified as 
possible,1(0.5%) as probable and 3(1.6%) as definite fungal infection. HRCT was done in 
32(16.7%) patients with probable fungal infection out of which 25   were reported as 
suggestive of fungal pneumonia. 
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       Among the patients with AML for LSC analysis 28(68.3%) underwent standard “3+7 
induction and 13(31.7%) had other induction which included truncated 
“7+3”,”3+3”,”5+5”® and standard pediatric BFM induction protocol. A total of 29 
patients(70.7%) achieved CR after first induction .Two(4.9%) patients underwent second 
induction, out of which 1(2.4%) achieved CR. Eight (19.5%) patients died during 
induction.  
 
                                 Table 10:Treatment related variables- Induction 
 
Variable Median/n 
(range)/(%) 
AMLn=192 
Median/n  
(range)/(%)  
AML LSC n=41 
Induction 
CR after 1 cycle 
CR after 2 cycles‡ 
Overall CR 
 
117(60.9) 
12 (6.25) 
129(67.15) 
 
29(70.7) 
01(2.4) 
30(73.1) 
ANC < 0.5 x 109/L 
Platelet< 20 x109/L 
22 (13-66) 
23 (18-61) 
22 (18-70) 
22(18-49) 
Day 10- 14 (n=182) 
residual disease∗ 
 
33(17.2) 02(4.9) 
Infection 
Fungal∗∗ 
Documented 
bacterial 
110(57.3) 
85 (44.3) 
 
18(9.4) 
25 (61) 
18(43.9) 
 
06(14.6) 
Induction death  47 (24.5) 08(19.5) 
               ∗ was arbitrarily defined as > 20% cellularity  with > 20% blasts.  
 
                     ∗∗ was defined based on S. Ascioglu et al. Defining Opportunistic Invasive 
Fungal     Infections in Immunocompromised Patients  with Cancer and 
Hematopoietic Stem Cell Transplants: An International Consensus. Clinical 
Infectious Diseases 2002; 34:7–14. 
                     ‡ 19  and 2 patients underwent 2nd induction in the AML  and AML LSC 
cohort respectively. 
 
                   ®5+5 included Mitoxantrone and Etoposide for 5days 
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Consolidation (Table 10) 
         For the 9 (4.7%) patients who had not been in remission after first induction 
3(1.5%) had an allogenic transplant, 5(2.6%) were discharged on palliation and 1(0.5%) 
patient was treated with intermediate dose cytosine. As mentioned before, 19 patients 
who were not in remission after first induction underwent a second induction. Seven 
(3.6%) patients did not achieve remission after 2 indcutions. Among these, 2(1%) 
underwent allo SCT and 5(2.6%) were treated with palliative therapy. Among the patients 
who achieved remission after the first induction 6(3.1%) were lost to follow up, 2 (1%) 
patients took further treatment at outside centre, 2 (1%) relapsed and were treated with 
palliative therapy. At the time of analysis 5(2.6%) patients had just completed induction 
and consolidation had not been started. Thus, 118(61.5%) patients (112 in CR1, and 6 
without achieving CR) received consolidation therapy. Those who received allo BMT 
were analysed according to intention to treat basis. For example, a patient without good 
risk cytogenetics who had an HLA matched donor was analysed in the allogenic SCT 
group irrespective of whether he received his graft in CR1 or CR2. Similarly, a patient 
who received HIDAC only for one cycle also was analysed in the HIDAC group. Thus, 
40(20.8%) patients underwent allo SCT, 25 (13%) auto SCT, 39(20.3%) HIDAC, and 
14(7.3%) patients received chemotherapy other than HIDAC.(Table11 and flow chart 2) 
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                                   Total events in/after consolidation = 47 
  
             Flow chart 2 describing the patients who were analysed in the study. 
 
Induction(192) 
CR1(117) 
Died(47) 
Lost for follow 
up(6) 
Treated 
outside(2) 
Relapsed(2) 
Remaining(28) 
Second 
induction(19) 
CR(12) No CR(7) 
Allo SCT(2) Palliation(5) 
Allogenic 
transplant(3) 
Palliation(5) 
Intermediate 
dose cytosine 
(1) 
Consolidation not 
started at the time 
of analysis (5) 
No follow up 
(2) 
Total 118 registered for 
consolidation 
Allo SCT(40) Auto SCT(25) Chemotherapy (53) 
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Allo SCT 
       Forty patients received allo SCT as consolidation (refer table 11).Of these 35(87.5%) 
had achieved CR and 5 patients had residual disease prior to conditioning. Of the patients 
who had achieved CR, 2 had a medullary relapse and one had a CNS relapse prior to the 
transplant. Graft source was G CSF mobilized peripheral blood stem cells (PBSC) in all. 
Thirty eight patients (95%) received graft from related donors and 2 received graft from 
unrelated donors. HLA of the donor was identical in 36(90%) patients, 5/6 match in 
3(7.5%) patients and 8/10 match in 1(2.5%) patient. The median cell dose was 5.92(range 
2.6 -10.8) x10 8 mononuclear cells/kg and median CD34 dose was 13.5(range 5.76-33) 
x106 cells /kg. Eighteen patients (45%)underwent allo SCT  without taking any further 
chemotherapy after induction; 11 (27.5%) took “ 5 +2” chemotherapy with daunorubicin 
and cytosine, 4 (10%)patients had “3+3” with Idarubicin and high dose Cytosine, 
one(2.5%) had Hyper C VAD  and 5(12.5%) had one or more cycles of HIDAC. Overall 
7(17.5%) patients died of non relapse causes of which 4(10%) were less than 100 days 
post transplant. Acute GVHD occurred in 18(45%) patients of which 14(35%) were grade 
2-4. Five (12.5%) patients relapsed of whom two (5%) received second transplant from 
the same donor and subsequently are in remission. 
Auto SCT 
       Twenty five (13%) patients underwent auto SCT. They received 1-3 cycles of high 
dose chemotherapy prior to auto SCT (refer table 11).All patients were in CR1 except 
one who was transplanted in CR2. Twenty three (92%) patients received atleast one dose 
of HIDAC. One patient received 2 cycles of “5+5” chemotherapy. One (4%) patient 
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received “3+3” followed by “5+5” chemotherapy. The conditioning regimen in all the 
patients was Busulfan/Cyclophosphamide. G CSF mobilized and cryopreserved 
peripheral blood stem cells was used as graft source. The median cell dose was 
5.80(range3.28 -13.99) x 10 8 mononuclear cells/kg and median CD34 dose of 4.4(range 
1.37-22.6)x 106 cells /kg. There was no treatment related mortality. The median time 
from CR to transplant was 146(range 76-249) days. Two (8%) patients in this cohort died 
in CR and 8(32%) patients relapsed. Of the patients who relapsed 2(8%) received allo 
SCT from matched unrelated donors and are in remission now. 
HIDAC 
       Thirty nine (20.3% of the total) patients received HIDAC as consolidation. Of these 
only 33(84.6%) received the second and 25(64.1%) received the third cycle. Two (5.1%) 
patients developed cerebellitis in cycle 2 and one (2.5%) patient in cycle3. Three (7.6%) 
patients died during second cycle of consolidation (refer table 11).Of the remaining, 12 
(30.4%) relapsed. 
Other chemotherapy 
       Among the 14(7.29%) patients who were treated with chemotherapy other than 
HIDAC as consolidation, 10(71.4%) received intermediate dose cytosine, 3(21.4%) 
received “5+2”, and 1(7.14%)  Gemtuzumab ozagamycin. One (7.14%) patient died of 
fungal pneumonia and 4 (28.56%) patients relapsed. 
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Table11:.Baseline characteristics and Treatment related variables- Consolidation AML  
 
Variables Median/n 
(range)/(%) 
 
Allo SCT 
n=40 
Median/n 
(range)/(%) 
 
Auto SCT 
n=25 
Median/n 
(range)/(%) 
 
HIDAC chemo 
n=39 
Median/n 
(range)/(%) 
 
Other chemo 
n=14 
Age in years 
Sex male 
female 
Subtype 
M0 
M1 
M2 
M4 
M5 
M6 
M7 
Secondary AML 
WBC at diagnosis x 109/l 
WBC index 
 
34(15-51) 
27(67.5) 
13(32.5) 
 
03(7.5) 
10(25) 
18(45) 
05(12.5) 
02(5) 
02(5) 
0(0) 
0(0) 
8.8(1.4-248.6) 
7.1(0.5-159.1) 
25(15-60) 
17(68) 
08(32) 
 
03(12) 
06(24) 
10(40) 
03(12) 
02(8) 
01(4) 
0(0) 
0(0) 
10.6(0.6-123) 
7.2(0.5-118.8) 
 36(17-60) 
23(59) 
16(41) 
 
03(7.7) 
09(23) 
23(59) 
02(5.1) 
01(2.6) 
01(2.6) 
0(0) 
0(0) 
9.5(0.9-101.7) 
6.0(0.4-91.53) 
47(22-57) 
09(64.3) 
05(35.7) 
 
03(21.4) 
01(7.1) 
05(35.8 ) 
02(14.3) 
02(14.3) 
0(0) 
0(0) 
01(7.1) 
46.5(1.9-167.9) 
29.7(1.3-97) 
Cytogenetic risk break up 
Not worked 
Good  
Intermediate 
Poor 
 
01(2.5) 
  0(0) 
28(70) 
11(27.5) 
 
01(4) 
01(4) 
20(80) 
03(12) 
 
01(2.6) 
14(35.9) 
21(53.8) 
03(7.7) 
 
02(14.3) 
02(14.3) 
07(50) 
03(21.4) 
Conditioning regimen ‡ 
Busulfan / 
Cyclophosphamide 
Fludraine /Melphalan 
Cyclophosphamide /TBI 
FLAG IDA+/- Melphalan 
 
15(37.5) 
15(37.5) 
3(7.5) 
7(17.5) 
 
 
25(100) 
 
n a 
  
n a 
ANC< 0.5x109/L(in days) 
 
13(9-26) 
 
 10(8-14) 
 
  19(11-39) 
 
 20(14-24) 
 
Death during consolidation 4(10) 0(0) 3(7.9) 1(7.7) 
Number of cyclesof  high 
dose chemo∗          
               Three 
                Two 
                One 
 
 
n a 
 
 
20(80) 
4(16) 
1(4) 
 
 
24(63.2) 
8(21) 
6(15.8) 
 
 
 n a  
‡ applicable only  for allo SCT and auto SCT patients 
∗ applicable only for auto SCT  and HIDAC patients. Refer text for  the pre transplant chemotherapy details 
of Allo SCT group. 
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Table12:Treatment related mortality(calculated within100 days of starting 
treatment) 
 
                                                                n (%) 
 
 
       Induction 
          n=47(24. 5%) 
 
   Allo SCT 
       n=4(10%) 
 
Auto 
SCT 
n=0 
 
HIDAC chemo 
      n=3(7.7%) 
 
Other chemo 
      n=1(7.1%) 
 
Fungal pneumonia-      24(51) 
Intracranial bleed-       1(2.1) 
Sepsis-                         9(19.2)* 
Hyper leucostasis-       1(2.1) 
Acute cardiotoxicity-   2(4.3) 
Acute renal failure-      1(2.1) 
Suspected pulmonary 
embolism-                    1(2.1) 
Fungal pneumonia 
 and sepsis-                 8(17.1)**      
 
 
Grd IV GVHD-    2(50) 
 
Hepatic failure-1(25) 
 
CMVcolitis-     1(25) 
 
 
 
nil 
 
Sepsis-              
2(66.7) 
Fungal  
pneumonia         
1(33.3) 
 
Fungal   
pneumonia    
1(100) 
 
*5 cases had documented gram negative sepsis. 
** 2cases had documented gram negative sepsis 
 
 
Screening for NPM1 and FLT3 Mutations (Tables 13 and 14) 
        Out of the 83 samples in which DNA was extracted 18 had NPM1 mutations, 14 had 
FLT3 ITD mutations and 2 had FLT3 TKD mutation. Patients with ITD and TKD 
mutations were analysed  as one group.  The baseline characteristics and treatment related 
characteristics of these patients are depicted in the tables 12 and 13.  All except 2 patients 
with NPM1 mutations had intermediate risk cytogenetics. No other variable showed 
significant difference between different subgroups. 
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Table 13:Baseline characteristics of patients with  NPM1 and FLT3   mutations 
(analysed separately) 
 
Variable 
n=82 
 
NPM1  
Mutated 
n=18  
Median/n 
(range)/(%) 
 
NPM1  
not mutated 
n=64  
Median/n 
(range)/(%) 
 
P 
value 
 
FLT3 
 mutated 
n=16 
 Median/n 
(range)/(%) 
 
FLT3 
not mutated 
n=66  
Median/n 
(range)/(%) 
 
 
P value 
Age 34(22-58) 
 
 
34.5(15-60) 
 
 
0.449 
 
 
34(17-58) 34.5(15-60) 0.829 
Sex 
Male 
Female 
 
09(50) 
09(50) 
 
 
41(64.1)    
23(35.9) 
 
0.290 
 
09(56.3) 
07(43.8) 
 
41(62.1) 
25(37.9) 
 
0.777 
WBC at 
diagnosis 
32.2(1.4-300) 19.9(0.7-248) 0.216 25.6(2.0-248) 53.5(2-387) 0.139 
WBC  
index 
21.3(0.5-285) 10.3(0.32-159) 0.102 17.4(0.54-159) 10.3(0.32-
285) 
0.168 
Cytogenetic 
Risk  group 
Good 
Intermediate 
Poor 
 
 
0(0) 
16(88.9) 
2(11.1) 
 
 
 
13(21) 
33(53.2) 
16(25.8) 
 
 
 
0.018 
 
 
 0(0) 
13(81.3) 
03(18.8) 
 
 
13(20.3) 
36(56.3) 
15(23.4) 
 
 
 
0.096 
CR 
(percentage) 
08(44.1) 41(64.1) 0.442 08(50) 41(62.1) 0.406 
Induction 
death 
(percentage) 
08(44.4) 15(23.4) 0.135 04(25) 19(28.8) 1.000 
OS+/- 1 SE * 
 
EFS+/- 1SE 
 
DFS+/- 1SE 
30.86+/-12.91 
 
27.01+/-11.86 
 
48.61+/-18.73 
45.24+/-7.12 
 
37.25+/-6.82 
 
53.84+/-8.69 
0.151 
 
0.155 
 
0.710 
37.50+/-14.99 
 
25.00+/-13.40 
 
33.33+/-17.21 
43.41+/-6.86 
 
37.77+/-6.59 
 
68.71+/-8.65 
0.832 
 
0.347 
 
0.013 
Relapses 
 n (  %) 
2(11.1) 18(28.1) 0.215 04(25) 16(24.4) 1.000 
Consolidation 
HIDAC 
Auto SCT 
Allo SCT 
Other Chemo 
 
02(25) 
02(25) 
03(37.5) 
01(12.5) 
 
10(25) 
07(17.5) 
10(35) 
09(22.5) 
 
 
0.912 
 
02(20) 
02(20) 
05(50) 
01(10) 
 
10(26.3) 
07(18.4) 
12(31.6) 
09(23.7) 
 
 
0.658 
 
*Estimated Kaplan Mier Survival values at a median follow up of 2 years 
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         Table 14: Baseline characteristics of patients with NPM1 and FLT3 mutations 
        (analysed in combination ) 
 
   *Estimated Kaplan Mier survival values at a median follow up of 2 years .For the     
NPM1mut FLT3mut  group only 1 year survival data was available 
£’mut’ denotes ‘mutated’ and ‘not’ denotes ‘not mutated’ 
 # This group was considered as reference for cox regression analysis 
 
Variable 
 
N=82 
NPM1# 
mut£ 
FLT3 not 
n=11 
Median/n(range)/(%) 
NPM1 
not 
FLT3 mut 
n= 09  
Median/n(range)/(%) 
NPM1 
not  
FLT3 
not n=55 
Median/n(range)/(%) 
NPM1 
mut 
FLT3 mut 
n=07 
Median/n(range)/(%) 
P value 
Age 34(24-58) 34(17-53) 35(15-60) 34(22-58) 0.803 
Sex 
Male 
Female 
 
04(36.4) 
07(63.6) 
 
04(44.4) 
05(55.6) 
 
37(67.3) 
18(32.7) 
 
05(71.4) 
02(28.6) 
 
0.167 
WBC at diagnosis 39.4(1.4-300) 40(8.4-248.6) 11.8(0.7-215) 22.2(2-119.9) 0.110 
WBC  
index 
27.4(0.5-285) 13.8(3.6-159) 6.5(0.32-142) 17.8(0.54-88) 0.140 
Cytogenetic 
Risk  group 
Good 
Intermediate  
Poor 
 
 
0(0) 
10(90.9) 
01(9.1) 
 
 
0(0) 
07(77.8) 
02(22.2) 
 
 
13(24.5) 
26(49.1) 
14(26.4) 
 
 
0(0) 
06(85.7) 
01(14.3) 
 
 
 
0.061 
CR (percentage) 05(45.5) 05(55.6)  36(65.5) 03(42.9) 0.462 
Induction death 
(percentage) 
05(45.5) 01(11.1) 14(25.5) 03(42.9) 1.000 
OS+/- 1 SE* 
 
EFS+/- 1SE 
 
DFS+/- 1SE 
32.73+/-14.97 
 
32.73+/-14.97 
 
60.00+/-21.91 
 
 
 
44.44+/-18.89 
 
29.63+/-17.46 
33.33+/-19.35 
 
45.65+/-07.62 
 
38.84+/-07.29 
 
58.57+/-09.36 
28.57+/-22.26 
 
21.43+/-17.81 
 
37.50+/-28.64 
 
 
0.489 
 
0.084 
Relapses 
 n (  %) 
01(9.1) 03(33.3) 15(27.3) 01(14.3) 0.490 
Consolidation 
HIDAC 
Other Chemo 
Auto SCT 
Allo SCT 
 
02(40) 
01(20) 
01(20) 
01(20) 
 
02(28.6) 
01(14.3) 
01(14.3) 
03(42.9) 
 
08(24.2) 
08(24.2) 
06(18.2) 
11(33.3) 
 
00(0) 
00(0) 
01(33.3) 
02(66.7) 
 
 
0.916 
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          Survival Data (Tables 15 and 16) 
       The overall survival (OS), event free survival (EFS) and disease free 
survival(DFS) were calculated for the whole cohort as well as for the different 
cytogenetic and molecular subgroups and the different modes of consolidation. 
The relationship between baseline characteristics and treatment related variables 
and the EFS was analysed using the logistic regression model. At a median follow 
up of two years  the Kaplan- Meier estimate of OS, EFS and  DFS was 47.30+/- 
4.30%, 37.52+/- 4.20%  and 54.49+/-5.38% respectively.(Figures 4 ,5 and 6).The 
difference in outcomes between the different cytogenetic and molecular 
subgroups as well as for the different modalities of consolidation did not show 
statistical significance(illustrated in figures 7and 8). However, when analysed  
using cox regression , age, WBC count at diagnosis(as a continuous variable), 
poor risk cytogenetics  and WBC index at diagnosis (as a continuous variable) 
significantly correlated with event free survival(table 15). The  disease free 
survival curves for the two subgroups above and below the median value (8.12) of  
WBC index were significant(p=0.0225).Similarly in the cohort for AML LSC 
analysis there was significant difference in the relapse free survival between the 
subgroups segregated according to stem cell frequency in post induction marrow 
sample. Multivariate analysis was done using cox regression-enter method where 
all the significant vaiables in predicting the EFS (age, WBC count, poor risk 
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cytogenetics and WBC index) were analysed  together by enter method, age and 
poor risk cytogenetics  retained significance. However, when analysed using cox 
regression forward stepwise method, where the most significant variable ( WBC 
index) was analysed against other variables, WBC index  was found to be the 
most significant variable. 
                                  Table 15: Baseline characteristics and impact on EFS 
 
 
 
            *These groups were considered as reference for cox regression analysis 
 
 
 
Variable 
n=192 
Median/n 
(range)/(%) 
Event n=104 
Median/n 
(range)/(%) 
 No Event 
 n=88 
RR 
(95% CI) 
P 
value 
Age in years 37(16-60) 33(15-57) 1.0(1.00-1.03) 0.045 
Sex 
Male* 
female 
 
64 (61.5) 
40 (38.5) 
 
56 (63.6) 
32 (36.4) 
 
 
0.8(0.58-1.27) 
 
0.446 
AML Subtype 
 
M0 
M1 
M2* 
M4 
M5 
M6 
M7 
Secondary AML 
 
 
10 (9.6) 
19 (18.3) 
50 (48.1) 
10 (9.6) 
05 (4.8) 
04 (3.8) 
02 (1.9) 
04 (3.8) 
 
 
05 (33.3) 
20 (22.7) 
45 (51.1) 
08  (9.1) 
07 (8.0) 
02 (2.3) 
01 (1.1) 
0   (0) 
 
 
1.1(0.54-2.09) 
0.8(0.50-1.45) 
 
0.9(0.46-1.83) 
0.7(0.29-1.86) 
1.2(0.44-3.38) 
2.6(0.64-11.03) 
2.5(0.89-6.87) 
 
 
0.868 
0.549 
 
0.819 
0.515 
0.704 
0.180 
0.082 
Hb(g/dl) 
WBC x 109/l 
Platelet x 109/l 
8.8(4.6-14) 
20.5(0.4-326) 
52 (3-387) 
8.65(3.8-13.1) 
9.6(0.6-167.9) 
47. 5(2-348) 
1.0(0.97-1.18) 
1.0(1.00-1.00) 
1.0(0.99-1.00) 
0.176 
0.012 
0.546 
CTG 
Good risk* 
Intermediate risk 
Poor risk 
 
07(7.2) 
68(70.1) 
22(22.7) 
 
14(16.9) 
53(63.9) 
16(19.3) 
 
 
2.0(0.92-4.40) 
2.4(1.04-5.78) 
 
 
0.079 
0.040 
NPM mutated* 
 Not mutated  
12(24.5) 
37(75.5) 
06(18.2) 
27(81.8) 
 
0.6(0.32-1.02) 
 
0.160 
FLT3 mutated 
 Not mutated* 
10(20.4) 
39(79.6) 
06(18.2) 
27(81.8) 
1.4(0.69-2.85) 0.350 
  
NPM mut FLT3 not* 
07(14.3) 04(12.1)   
 
NPM mut FLT3mut 
05(10.2) 02(6.1) 1.3 (0.40-4.07) 0.678 
 
NPM not FLT3 not 
32(65.3) 23(69.7) 0.7(0.294-1.52) 0.336 
 
NPM not FLT3 mut 
05(10.2) 04(12.1) 0.8 (0.26-2.60) 0.735 
WBC Index at 
diagnosis 
11.1 (0.1-285) 5.9(0.4-118.9) 1.0(1.00-1.01) 0.002 
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        Table 16: Treatment related parameters  and impact on EFS 
 
variable         Median/n(range)/(%) 
   Event                        No event 
RR(95% CI) P value 
Induction 
CR after 1 cycle* 
CR after 2 cycles 
 
41 (89.1) 
05 (10.9) 
 
76 (91.6) 
07 (8.4) 
 
 
0.8(0.33-2.16) 
 
 
0.730 
Consolidation  
HIAC 
Other Chemo 
Auto SCT 
Allo SCT * 
 
15 (32.6) 
06 (13.0) 
10 (21.7) 
15 (32.6) 
 
24 (33.3) 
08 (11.1) 
15 (20.8) 
25 (34.7) 
 
1.3(0.67-2.85) 
1.6(0.64-4.30) 
1.0(0.47-2.35) 
 
0.368 
0.298 
0.895 
 
 
*These groups were considered as reference for cox regression analysis 
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                                                         Overall Survival 
Figure4: Kaplan Meier estimate of Overall Survival at a median follow up of 2 years was 47.30+/-
04..30%. 
 
 
 
 
 
 
 
                                                   Event Free Survival 
 
Figure 5: Kaplan Meier estimate of Event Free Survival at a median follow up of 2 years was 
37.52+/-04.20%. 
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                                                Disease Fee Survival 
 
Figure 6: Kaplan Meier estimate of Disease Free Survival at a median follow up of 2 years was 
54.49+/-05.38%. 
 
 
 
 
 
                            Figure 7: EFS in the different cytogenetic risk groups 
Good n=21 
Intermediate n=121 
Poor n=38 
p = 0.1103 
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                        Figure 8:   EFS in different modalities of consolidation. 
 
 
 
 
 
 
                    Figure 9: Disease Free Survival in subgroups according to WBC index 
 
Allo SCT  n=40 
Auto SCT  n=25 
Chemo   n= 53 
p=0.6574 
<8.12 n=64 
 >8.12  n=66 
p =0.0225 
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LSC analysis (Tables 17and 18) 
Quantitation of LSCs in the bone aspirate samples   at diagnosis and in the post induction 
marrow were done in 41 patients with AML. At diagnosis the CD34 + cells quantified as 
percentage of the gated population in forward scatter (FSC) vs side scatter (SSC) was 
13.5 (range 0.02-81.6). Similarly CD34+CD38- and CD34+ CD38- CD123+ fractions were 
quantified (refer tables 17 and 18)).The expression of adhesion molecules VLA4 and VLA5 on 
the CD34+ CD38- CD123+ fraction as well as on the original gated population (i.e.FSC vs SSC) 
was also quantified. The post induction AML marrow sample and the APML samples were also 
analysed in a similar way. Thus the CD34+ and CD34+ CD38- in the day 10-14 marrow 
when quantified and analysed as a continuous variable was significant to predict 
events(p= 0.025 and 0.024 respectively).The CD34+CD38- cell compartment also 
seemed to predict relapse and refractory disease. However a median  and quadrantile 
analysis were not significant. Hence we analysed survival against CD34+CD38- cell 
frequency above and below an arbitrary cut off of 0.2% of total gated population on FSC-
SSC. This showed statistical significance with a p value of 0.031 (Figure 10). 
   
               Figure 10:Relapse free survival  of patients according to residual CD34+CD38-  cell 
                                frequency in the post induction bone marrow 
n =22 
n= 13 
p=0.031 
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However when we analysed the expression of adhesion molecules on leukemic stem cells 
and their absolute expression on all blasts, none of the p values were significant when 
analysed against EFS. 
Table 17: LSC analysis AML  - Bone Marrow Flow Cytometric evaluation at 
diagnosis versus EFS 
 
 
Variable n=41 
Median/n 
(range)(%) 
Bone Marrow at 
diagnosis(AML) 
 
RR(95%CI) 
 
P value 
CD 34 +ve  as % of total gated 
population 
           
 13.5(0.02-81.6) 
 
0.998(0.981-1.016) 
 
0.828 
CD34+CD38- as % of  total 
gated population 
        
0.095(0.00-49.00) 
 
1.008(0.970-1.047) 
 
0.683 
CD34+CD38CD123+(LSC)as 
% of total gated population  
          
  0.02(0.00-37.5) 
 
1.008(0.956-1.062) 
 
0.773 
Absolute count of 
CD34+CD38-CD123+ 
 
11.07(0.00-2447.5) ∗ 
 
1.000(1.000-1.001) 
 
0.392 
VLA4 expression on LSC as 
%of total gated population 
          
 0.01(0.00-6.57) 
 
1.032(0.773-1.380) 
 
0.829 
VLA5 expression on LSC as % 
of total gated population 
             
0.03(0.00-34.8) 
 
1.011(0.958-1.067) 
 
0.687 
VLA4 expression on gated 
population of blasts 
           
 84.8  (3.83-99) 
 
1.004(0.986-1.022) 
 
0.652 
VLA5 expression on gated 
population of blasts 
            
81.25(2.0-97.2) 
 
1.008(0.985-1.032) 
 
0.478 
∗ Bone marrow TC was available on 29 paitents with AML at diagnosis  
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Table 18:LSC  analysis AML  -Flow Cytometric evaluation of post induction      
Bone Marrow on Day10-14 versus EFS 
 
 
 
 
 
 
 
 
 
 
Variable (n=35) 
 
Median/n 
(range)(%) 
 
 
 
RR(95%CI) 
 
 
P value 
CD 34 +ve  as % of total gated 
population 
 
0.38 (0.04-68.4) 
 
1.038(1.005-1.071) 
 
0.025 
CD34+CD38- as % of  total 
gated population 
 
0.05 (0.00-5.11) 
 
1.627(1.038-2.55) 
 
0.034 
CD34+CD38CD123+(LSC)as 
% of total gated population  
 
0.02 (0.00-6.70) 
 
1.286(0.898-1.840) 
 
0.169 
Absolute count of 
CD34+CD38-CD123+ 
 
0.20  (0.00-53.6) 
 
1.036(0.990-1.084) 
 
0.131 
VLA4 expression on LSC as 
%of total gated population 
 
0.02  (0.00-1.02) 
 
5.185(0.616-43.642) 
 
0.130 
VLA5 expression on LSC as % 
of total gated population 
 
0.02  (0.00-6.70) 
 
0992(0.977-1.007) 
 
0.303 
VLA4 expression on gated 
population 
 
82.3 (0.96-98.7) 
 
0.996(0.977-1.016) 
 
0.721 
VLA5 expression on gated 
population 
 
 41.2 (2.64-78.3) 
 
1.002(0.973-1.032) 
 
0.878 
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AML is a heterogenous disease with various subgroups, be it morphological, cytogenetics 
vise or according to the molecular markers. There is very little data from the developing 
world regarding the clinical profile and treatment outcome in AML.We found a sex ratio 
(1.67). This could largely be attributable to the social situation in India, which will be 
reflected in any cohort of patients who seek medical attention. Among the FAB subgroup 
M2 was most common (49.5%) which was comparable to that of CALGB data (37%). 
The cytogenetic classification showed a predominance of the intermediate risk group 
which was comparable to that of the data from ECOG4 and SWOG.  
Induction Therapy  
         The overall CR rate after 1 or 2 cycles of induction was 67.15%.This is comparable 
to the data by Hugo.F.Fernandez et. al. published in NEJM which reported a CR of 
57.3% in the group who received Daunorubucin 45mg/m2.We had a high incidence of 
death rate (24.5%) during induction therapy. Equally alarming was the incidence of 
fungal infections (44.3%).This brings to light the immediate need for better policies in 
antifungal prophylaxis and treatment. 
Consolidation Therapy 
         Of the 192 patients who underwent induction, 118 (61.45%) patients entered 
consolidation phase. The results of the different subgroups have to be interpreted with 
caution. Whereas the patient segregation between allo SCT group and the rest was based 
on an intention to treat basis, the same could not be applied to the subgroups within 
patients who did not have a matched donor (i.e. Auto SCT vs HIDAC).However this data 
provides us with a significant baseline on which we can build our future approaches 
towards consolidation therapy. Perhaps the most striking fact is the zero treatment related 
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mortality in the subgroup who received auto SCT. This is very reassuring, as the 
traditional argument against an auto SCT has been that the lesser relapse rates were offset 
by higher treatment related mortality. 
Molecular markers FLT3 and NPM1 mutations 
        As the number of samples where the data on FLT3, NPM1 mutation status was 
known was small, no meaningful conclusions could be made regarding their impact on 
survival. However, this provides us a rough idea of the baseline characteristics across the  
different subgroups. 
Survival 
          The Kaplan Meier survival curves were similar to the data from the different 
cooperative groups from the west. However our numbers were small and the median 
follow up was short. Long term follow up will provide us more information regarding 
late relapses and deaths. Although the cytogenetic subgroups did not show significant 
differences in the Kaplan Meier estimate of EFS, (this could be due to the small 
numbers), there was an evident trend towards better outcome in the good risk subgroups. 
Moreover, the poor risk cytogentic subgroup showed significantly bad outcome when 
analysed against EFS using a cox regression model. Similarly, age, WBC count and 
WBC index were found to be significant when analysed as a continuous variable against 
EFS. The ECOG/SWOG4 data had also shown significance with age and WBC count at 
diagnosis.  
WBC index 
      WBC index was initially used by the French group113 to risk stratify their patients 
with t(8;21). We applied this to the whole AML cohort. When analysed as a continous 
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variable against EFS and DFS, the WBC index was found to be significant (p value-
0.002).When analysed as two groups above and below the median value (8.12) it retained 
significance with DFS. This is a finding of great importance in our setting. This, unlike 
cytogenetics, is readily available at diagnosis and will help us in identifying a subset of 
patients with less risk of relapse. In a resource poor setting like ours, this can help us in 
offering cost effective treatment options to this subset of good risk patients. 
Leukemic Stem cells 
       Rationale in quantifying LSCs by a set of immunophenotypic markers at diagnosis 
and in postinduction marrow was that LSCs are quiescent cells which are resistant to 
conventional chemotherapy and the residual LSCs in the post induction marrow sample 
would predict relapse. Thus the CD34+ and CD34+ CD38- in the day 10-14 marrow 
when quantified and analysed as a continuous variable was significant to predict events. 
A similar study was done by Anna van Rhenen71et al. in Netherlands. They quantified 
CD34+CD38- cells at diagnosis, at remission and after each consolidation. Ours is the 
first study to look at the CD34+CD38-   cell frequency in a post induction marrow. This 
is a pilot study ,  the numbers were small and hence a multivariate analysis was not 
attempted, but it certainly seems to be worth pursuing this in a larger cohort of patients 
prospectively. If these results are indeed validated then it could translate into forming 
post induction treatment algorithms with better antileukemic potency for those patients 
with high residual stem cell frequency. 
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1. The male: female ratio was 1.67 and the median age at diagnosis was 34 years. 
 
2. The most common FAB subtype was AML M2 (49.5%) followed by M1 (20.3%). 
 
3. The median WBC count at diagnosis was 12.6 x 109 /l. 
 
4. The majority of the patients belonged to intermediate risk cytogenetic subgroup 
(63%) followed by poor risk(19.8%) and good risk(10.9%). 
 
5. One hundred and seventeen patients (60.9%) achieved remission (CR)after one 
cycle of induction and another 12 (6.25%)  after two cycles. 
 
6. Thirty three patients (17.2%)  had  residual disease in the day 10-14 bone marrow 
defined as >20 percent blasts with >20% cellularity. 
 
7. Fourty seven (24.5%) patients died during induction, 33(70.2%) of them due to 
invasive fungal infections.  
 
8. Eighty five (44.3%) patients had documented fungal infection(as defined by the 
international consensus criteria) during induction. 
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9. One hundred and eighteen (61.45%) patients took consolidation therapies; Out of 
these,40(33.9%) were treated with alloSCT, 25(21.2%) had auto SCT, 39(33%) 
had HIDAC and 14(11.9%) had other chemotherapies as consolidation. 
 
10. The Kaplan Meier survival curves showed similar pattern as that of the western 
data; but the median followup was short. 
 
11. The difference in overall and event free survival among different cytogenetic 
subgroups was not statistically significant. This might be due to the smaller 
numbers. The good risk cytogenetic subgroup did certainly show a trend towards 
better outcome. 
 
12. Age, poor risk cytogenetics, WBC count and WBC index at diagnosis showed 
statistical significance against EFS using a cox regression model. 
 
13. We found that the WBC index at diagnosis could predict the risk of relapse across 
the cytogenetic subgroups among the patients who achieved remission.  
 
14. In the cohort of patients where LSC quantification was done, it was found that the 
frequency of CD34+CD38- cells remaining in a post induction marrow predicted  
early relapse and refractory disease. 
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15. This study justifies our treatment algorithm in young adults with AML as the 
results are comparable with the western data. It will provide a baseline from 
which future therapeutic modifications can be planned. 
 
16. The WBC index could identify a subgroup of patients across the cytogenetic 
subgroups with a low risk of relapse. This needs to be validated in larger numbers. 
 
17. Quantifying CD34+CD38- cells in the post induction bone marrow will identify a 
subset of patients with risk of early relapse. These patients might benefit from 
intensified and targeted post induction treatment algorithms. 
 
18. This analysis also gives us an idea about the baseline characteristics of patients 
with NPM1 and FLT3 mutations, although a comparison between the different 
subgroups could not be meaningfully interpreted due to the small numbers.  
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